Your browser doesn't support javascript.
loading
Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines.
Meulendijks, Didier; Henricks, Linda M; van Kuilenburg, André B P; Jacobs, Bart A W; Aliev, Abidin; Rozeman, Lisette; Meijer, Judith; Beijnen, Jos H; de Graaf, Hiltje; Cats, Annemieke; Schellens, Jan H M.
Afiliación
  • Meulendijks D; Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. didier.meulendijks@gmail.com.
  • Henricks LM; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. didier.meulendijks@gmail.com.
  • van Kuilenburg AB; Dutch Medicines Evaluation Board (CBG-MEB), Utrecht, The Netherlands. didier.meulendijks@gmail.com.
  • Jacobs BA; Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
  • Aliev A; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Rozeman L; Department of Clinical Chemistry, Laboratory Genetic Metabolic Diseases, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
  • Meijer J; Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
  • Beijnen JH; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • de Graaf H; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Cats A; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Schellens JH; Department of Clinical Chemistry, Laboratory Genetic Metabolic Diseases, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Cancer Chemother Pharmacol ; 78(4): 875-80, 2016 10.
Article en En | MEDLINE | ID: mdl-27544765
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Dihidrouracilo Deshidrogenasa (NADP) / Deficiencia de Dihidropirimidina Deshidrogenasa / Capecitabina / Fluorouracilo / Antimetabolitos Antineoplásicos Tipo de estudio: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Chemother Pharmacol Año: 2016 Tipo del documento: Article País de afiliación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Dihidrouracilo Deshidrogenasa (NADP) / Deficiencia de Dihidropirimidina Deshidrogenasa / Capecitabina / Fluorouracilo / Antimetabolitos Antineoplásicos Tipo de estudio: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Chemother Pharmacol Año: 2016 Tipo del documento: Article País de afiliación: Países Bajos